Abnova (Taiwan) Corporation (4133.TW)
TWD 28.0
(-2.95%)
TWD 28.0
(-2.95%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -415.8 Million TWD | -16.74% |
| 2022 | -356.18 Million TWD | -19.06% |
| 2021 | -299.16 Million TWD | -23.78% |
| 2020 | -241.7 Million TWD | -61.63% |
| 2019 | -149.54 Million TWD | -3.37% |
| 2018 | -144.66 Million TWD | 22.57% |
| 2017 | -186.82 Million TWD | -15.63% |
| 2016 | -161.56 Million TWD | -59.9% |
| 2015 | -101.04 Million TWD | 79.9% |
| 2014 | -502.81 Million TWD | -2.31% |
| 2013 | -491.45 Million TWD | -0.94% |
| 2012 | -486.88 Million TWD | 14.59% |
| 2011 | -570.05 Million TWD | 3.03% |
| 2010 | -587.86 Million TWD | -4.26% |
| 2009 | -563.83 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -452.22 Million TWD | -8.76% |
| 2024 Q2 | -449.43 Million TWD | 0.62% |
| 2023 Q3 | -430 Million TWD | -3.05% |
| 2023 Q2 | -417.28 Million TWD | -10.72% |
| 2023 Q4 | -415.8 Million TWD | 3.3% |
| 2023 Q1 | -376.89 Million TWD | -5.82% |
| 2023 FY | -415.8 Million TWD | -16.74% |
| 2022 Q3 | -351.27 Million TWD | -15.18% |
| 2022 FY | -356.18 Million TWD | -19.06% |
| 2022 Q4 | -356.18 Million TWD | -1.4% |
| 2022 Q2 | -304.96 Million TWD | -0.26% |
| 2022 Q1 | -304.18 Million TWD | -1.68% |
| 2021 Q2 | -281.51 Million TWD | -13.05% |
| 2021 Q4 | -299.16 Million TWD | -9.81% |
| 2021 Q1 | -249.01 Million TWD | -3.03% |
| 2021 FY | -299.16 Million TWD | -23.78% |
| 2021 Q3 | -272.45 Million TWD | 3.22% |
| 2020 Q3 | -204.2 Million TWD | -16.29% |
| 2020 FY | -241.7 Million TWD | -61.63% |
| 2020 Q1 | -150.96 Million TWD | -0.95% |
| 2020 Q2 | -175.6 Million TWD | -16.32% |
| 2020 Q4 | -241.7 Million TWD | -18.36% |
| 2019 FY | -149.54 Million TWD | -3.37% |
| 2019 Q4 | -149.54 Million TWD | -5.82% |
| 2019 Q3 | -141.31 Million TWD | 8.12% |
| 2019 Q1 | -133.58 Million TWD | 7.66% |
| 2019 Q2 | -153.8 Million TWD | -15.14% |
| 2018 FY | -144.66 Million TWD | 22.57% |
| 2018 Q2 | -128.48 Million TWD | 1.37% |
| 2018 Q3 | -98.8 Million TWD | 23.1% |
| 2018 Q1 | -130.26 Million TWD | 30.27% |
| 2018 Q4 | -144.66 Million TWD | -46.41% |
| 2017 Q4 | -186.82 Million TWD | 11.87% |
| 2017 Q2 | -205.32 Million TWD | 2.15% |
| 2017 FY | -186.82 Million TWD | -15.63% |
| 2017 Q1 | -209.84 Million TWD | -29.88% |
| 2017 Q3 | -211.99 Million TWD | -3.25% |
| 2016 Q3 | -179.66 Million TWD | -19.59% |
| 2016 FY | -161.56 Million TWD | -59.9% |
| 2016 Q4 | -161.56 Million TWD | 10.07% |
| 2016 Q2 | -150.22 Million TWD | -65.67% |
| 2016 Q1 | -90.67 Million TWD | 10.26% |
| 2015 FY | -101.04 Million TWD | 79.9% |
| 2015 Q4 | -101.04 Million TWD | 4.45% |
| 2015 Q3 | -105.75 Million TWD | 72.71% |
| 2015 Q2 | -387.57 Million TWD | 22.19% |
| 2015 Q1 | -498.09 Million TWD | 0.94% |
| 2014 Q3 | -467.65 Million TWD | 9.06% |
| 2014 FY | -502.81 Million TWD | -2.31% |
| 2014 Q4 | -502.81 Million TWD | -7.52% |
| 2014 Q2 | -514.22 Million TWD | -3.42% |
| 2014 Q1 | -497.22 Million TWD | -1.17% |
| 2013 Q3 | -471.45 Million TWD | 12.77% |
| 2013 Q4 | -491.45 Million TWD | -4.24% |
| 2013 FY | -491.45 Million TWD | -0.94% |
| 2013 Q1 | -518.83 Million TWD | -6.56% |
| 2013 Q2 | -540.48 Million TWD | -4.17% |
| 2012 Q1 | -575.72 Million TWD | -0.99% |
| 2012 Q4 | -486.88 Million TWD | -1.07% |
| 2012 FY | -486.88 Million TWD | 14.59% |
| 2012 Q2 | -581.76 Million TWD | -1.05% |
| 2012 Q3 | -481.74 Million TWD | 17.19% |
| 2011 Q4 | -570.05 Million TWD | -8.41% |
| 2011 Q1 | -594.69 Million TWD | -1.16% |
| 2011 Q2 | -627.63 Million TWD | -5.54% |
| 2011 Q3 | -525.82 Million TWD | 16.22% |
| 2011 FY | -570.05 Million TWD | 3.03% |
| 2010 Q4 | -587.86 Million TWD | 0.0% |
| 2010 FY | -587.86 Million TWD | -4.26% |
| 2009 FY | -563.83 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Apex Biotechnology Corp. | -201.21 Million TWD | -106.649% |
| Sinphar Pharmaceutical Co.,Ltd. | 870.53 Million TWD | 147.765% |
| Panion & Bf Biotech Inc. | 193.2 Million TWD | 315.213% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 939.54 Million TWD | 144.256% |
| GenMont Biotech Incorporation | 2.71 Million TWD | 15432.19% |
| Adimmune Corporation | 685.12 Million TWD | 160.691% |
| Tanvex BioPharma, Inc. | 1.35 Billion TWD | 130.777% |
| Polaris Group | -2.41 Billion TWD | 82.81% |
| Energenesis Biomedical CO.,LTD. | -246.6 Million TWD | -68.611% |
| UnicoCell Biomed Co., Ltd. | 54.43 Million TWD | 863.933% |
| PELL Bio-Med Technology Co. Ltd. | 4.88 Million TWD | 8618.931% |